Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 31,346 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study participants Clear all
Completed Not applicable Interventional Results available

Examining Feasibility, Acceptability, and Sustainability of a Novel Personalized Smartphone Intervention for Suicide - Open Trial

NCT05180383
View directory record Official record
Conditions
Suicide and Self-harm, Suicide, Suicide, Attempted, Suicidal Ideation
Interventions
Mobile Application to Prevent Suicide (MAPS)
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Active, not recruiting Phase 2 Interventional

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

NCT05751941
View directory record Official record
Conditions
Prostate Cancer, Metastatic Prostate Cancer
Interventions
Abiraterone, Enzalutamide, Apalutamide, Sipuleucel-T
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

NCT07005154
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Interventions
ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
12
States / cities
Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Recruiting Not applicable Interventional

High-Resolution PET-CT Imaging for Surgical Margin Visualization

NCT06915454
View directory record Official record
Conditions
Cancer, Solid Malignant Tumors, SCC - Squamous Cell Carcinoma, HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Interventions
Intra-op PET/CT Specimen Scanner
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07123454
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
AZD4512, Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Irvine, California • Jacksonville, Florida • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Completed Not applicable Interventional

Evaluation of Arts-Based Storytelling Program in Adolescents With Diabetes

NCT07625254
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Arts-Based Storytelling Workshop Series
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Not listed Phase 3 Interventional

Enhancing Rehabilitation After Stroke

NCT00868010
View directory record Official record
Conditions
Ischemic Stroke
Interventions
donepezil, placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Warren, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Nov 15, 2026, 5:56 AM EST
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Validation and Usability Study of the SleepView+ Home Sleep Testing System for the Evaluation of Moderate to Severe Obstructive Sleep Apnea.

NCT07476313
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
SleepView+
Device
Lead sponsor
Beacon Biosignals
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
4
States / cities
Redwood City, California • Rochester, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Genetic Studies in Familial Dementia

NCT04680013
View directory record Official record
Conditions
Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
4,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Nov 15, 2026, 5:56 AM EST
Completed Phase 4 Interventional Results available

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

NCT03093480
View directory record Official record
Conditions
Hemophilia A With Inhibitors
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Nov 15, 2026, 5:56 AM EST
Withdrawn Phase 1 Interventional

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

NCT02658396
View directory record Official record
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Interventions
GO-203-2C, Bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Nov 15, 2026, 5:56 AM EST
Active, not recruiting Phase 2 Interventional Results available

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

NCT03505762
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)

NCT04875962
View directory record Official record
Conditions
Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
40 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
6
States / cities
Long Beach, California • Bay Harbor Islands, Florida • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Nov 15, 2026, 5:56 AM EST
Completed Phase 1Phase 2 Interventional Results available

Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain

NCT00129246
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Naltrexone, Bupropion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Nov 15, 2026, 5:56 AM EST
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

NCT03377361
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
Interventions
Nivolumab, Trametinib, Ipilimumab, Regorafenib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Nov 15, 2026, 5:56 AM EST
Completed Phase 3 Interventional Results available

A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years

NCT05101486
View directory record Official record
Conditions
Respiratory Syncytial Virus Prevention
Interventions
Ad26.RSV.PreF-based Vaccine
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years to 75 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Athens, Alabama • Vestavia Hills, Alabama • Phoenix, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 15, 2026, 5:56 AM EST
Terminated Phase 2 Interventional Results available

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

NCT05306873
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Nov 15, 2026, 5:56 AM EST
Not listed Phase 1Phase 2 Interventional

LIWA for Treatment of Alzheimer Patients

NCT02204969
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lithia water, Transcranial Magnetic stimulation
Dietary Supplement · Device
Lead sponsor
American Society Of Thermalism And Climatology Inc
Other
Eligibility
50 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Nov 15, 2026, 5:56 AM EST
Completed Phase 4 Interventional

C-Raven, a Virtual Tobacco Cessation Intervention in the Community

NCT06545669
View directory record Official record
Conditions
Tobacco Dependence
Interventions
C-Raven Virtual Tobacco Cessation Counseling, Nicotine Replacement Product, Community Health Worker, Lung Cancer Screening
Behavioral · Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Not yet recruiting Not applicable Interventional

Community Intervention to Improve CVD Risk Factor Control in Young American Indians

NCT06230705
View directory record Official record
Conditions
Cholesterol, Elevated, Diabetes Mellitus
Interventions
Guided management, Self management
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 39 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Nov 15, 2026, 5:56 AM EST
Terminated Phase 3 Interventional Results available

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

NCT05946551
View directory record Official record
Conditions
COVID-19
Interventions
Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Nov 15, 2026, 5:56 AM EST
Completed Phase 2 Interventional

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

NCT06522997
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
BAY3283142, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
24
States / cities
Huntsville, Alabama • Chula Vista, California • San Dimas, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 15, 2026, 5:56 AM EST
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

NCT01994382
View directory record Official record
Conditions
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
Interventions
Cerdulatinib, Rituximab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
23
States / cities
Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Nov 15, 2026, 5:56 AM EST
Terminated Phase 1 Interventional

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

NCT05627323
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain
Interventions
CHM-1101 CAR-T cells
Biological
Lead sponsor
Chimeric Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Duarte, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Nov 15, 2026, 5:56 AM EST